Cover Image

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Background: Our previous studies have shown that Yindan Jiedu granules (YDJDG) can effectively treat coronavirus disease 2019 (COVID-19); however, the high infectivity and the immune escape potential of the Omicron variant BA.2 make it more difficult to control, and patients with high-risk factors p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Feng (Author), Yao Liu (Author), Long Liu (Author), Yuyong Jiang (Author), Yixin Hou (Author), Yang Zhou (Author), Rui Song (Author), Xiaoyou Chen (Author), Xianbo Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019
by: Jingyuan Liu, et al.
Published: (2021)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
by: Sivaprakasam T. Selvavinayagam, et al.
Published: (2022)

Subchronic toxicity of herbal compound "Jiedu Huayu" granules in rats
by: Minggang Wang, et al.
Published: (2017)

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees
by: Francesca Dapporto, et al.
Published: (2022)

Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market
by: Mingyu Luo, et al.
Published: (2023)

Corrigendum: Analysis of a super-transmission of SARS-CoV-2 omicron variant BA.5.2 in the outdoor night market
by: Mingyu Luo, et al.
Published: (2023)

Epidemiological characteristics of a local COVID-19 outbreak caused by Omicron (BA.2.2) variant in Henan province
by: Jing-jing PAN, et al.
Published: (2022)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
by: Urvashi B. Singh, et al.
Published: (2023)

Jiedu Tongluo Granules Ameliorates Post-stroke Depression Rat Model via Regulating NMDAR/BDNF Signaling Pathway
by: Aimei Zhao, et al.
Published: (2021)

Transmission characteristics of a COVID-19 outbreak caused by Omicron variant BA.5.2 in Yiwu city, China
by: Xiaoxiao WANG, et al.
Published: (2023)

SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil.
by: Francisco P Freire-Neto, et al.
Published: (2022)

Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2
by: Alwaleed Behzad, et al.
Published: (2024)

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
by: Kana Fujimoto, et al.
Published: (2022)

Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2
by: Weijie Zhong, et al.
Published: (2023)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022)

Characteristics of Omicron variant-induced SARS-CoV-2 reinfections in Chengdu, China
by: Yingxue DAI, et al.
Published: (2023)

Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China
by: Peng Yang, et al.
Published: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study
by: Xiaqing Zhang, et al.
Published: (2023)

Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
by: Chengzhuo Tong, et al.
Published: (2022)

Age-specific transmission dynamics under suppression control measures during SARS-CoV-2 Omicron BA.2 epidemic
by: Wenlong Zhu, et al.
Published: (2023)

Case report: Severe acute hepatitis in a 22-month-old Chinese boy with Omicron sub-variant BA.2.38
by: Xinying Chen, et al.
Published: (2022)

Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia
by: Abeer N. Alshukairi, et al.
Published: (2023)

Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland
by: Chris Robertson, et al.
Published: (2023)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
by: Rahatul Islam, et al.
Published: (2023)

Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China
by: Jichao Sha, et al.
Published: (2023)

The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in Taiwan
by: Jih-Jin Tsai, et al.
Published: (2024)

Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
by: Shengnan Yin, et al.
Published: (2022)

Multisystem inflammatory syndrome (MIS-C) with SARS-CoV-2 omicron variant BA.2.38 in a four-year-old Chinese girl: A case report
by: Wen-yuan Wang, et al.
Published: (2022)

Characteristics of local COVID-19 cases aged ≥ 60 years in Zhejiang province during epidemic period dominantly due to SARS-CoV-2 Omicron variant infection
by: Bi-yao LIU, et al.
Published: (2022)

Omicron variant in the current SARS-CoV-2 pandemic
by: Kaveh Nasiri, et al.
Published: (2022)

Machine learning-based model for predicting the esophagogastric variceal bleeding risk in liver cirrhosis patients
by: Yixin Hou, et al.
Published: (2023)

Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
by: Haruka Maeda, et al.
Published: (2023)

Omicron variant of SARS-CoV-2 imposes a new challenge for the global public health
by: Zepeng Xu, et al.
Published: (2022)

Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
by: Kimiko Tomioka, et al.
Published: (2023)

Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection
by: Alina Seidel, et al.
Published: (2023)

Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
by: Wenjing Ye, et al.
Published: (2023)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
by: Freja Cordelia Møller Kirsebom, et al.
Published: (2022)

As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
by: Ren Xu, et al.
Published: (2022)

Importation of SARS-CoV-2 Omicron variant in Beijing, China
by: Fu Li, et al.
Published: (2022)

Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant
by: Nirmitee Mulgaonkar, et al.
Published: (2023)